微信在线咨询
| 产品编号 | 产品名称 | 产品包装 | 产品价格 |
| SM6040-10mM | 人参皂苷Rg1 (98%, HPLC) | 10mM×0.2ml | 90.00元 |
| SM6040-25mg | 人参皂苷Rg1 (98%, HPLC) | 25mg | 120.00元 |
| SM6040-100mg | 人参皂苷Rg1 (98%, HPLC) | 100mg | 408.00元 |
| 中文名 | 人参皂苷Rg1 |
| 英文名 | Ginsenoside Rg1 |
| 中文别名 | - |
| 英文别名 | Ginsenoside A2; Panaxoside A; Sanchinoside C1; Panaxoside Rg1 |
| 来源 | 人参Panax ginseng C. A. Meyer |
| 化合物类型 | 萜类(Terpenoids)>三萜>达玛烷型四环三萜皂苷 |
| 化学式 | C42H72O14 |
| 分子量 | 801.01 |
| CAS号 | 22427-39-0 |
| 纯度 | 98%, HPLC |
| 溶剂/溶解度 | DMSO: ≥ 100 mg/ml (124.84 mM) |
| 溶液配制 | 10mg加入1.25ml DMSO，或者每8.01mg加入1ml DMSO，配制成10mM溶液。 |
| 产品描述 | Ginsenoside Rg1 is one of the major active components of ginseng. Ginsenoside Rg1 displays promising effects by reducing cerebral Aβ levels. Ginsenoside Rg1 also reduces NF-κB nuclear translocation. | ||||
| 信号通路 | - | ||||
| 靶点 | Aβ1-42 | NF-κB nuclear translocation | p-IκBα | p-p65 | - |
| IC50 | - | - | - | - | - |
| 体外研究 | Ginsenoside Rg1 promotes the proliferation and differentiation of human dental pulp cells (hDPCs). The proliferative ability of hDPCs in Ginsenoside Rg1 is significantly enhanced (p<0.05), especially in the Ginsenoside Rg1 (5 μM) group. ALP activity and gene expressions of DSPP and DMP1 are increased in the induction group, Ginsenoside Rg1 group, and their combination group compared with the control group (p<0.05). In the RAW264.7 cells stimulated by lipopolysaccharides (LPS) , the level of p-IκBα and p-p65 is significantly higher than in controls and PPAR-γ levels are significantly lower. Treatment with Rg1 vitro inhibits IκBα phosphorylation, reduces NF-κB nuclear translocation and upregulates PPAR-γ expression. | ||||
| 体内研究 | In the inflamed joints of adjuvant-induced arthritis (AIA) rats, the level of p-IκBα and p-p65 is significantly higher than in controls and PPAR-γ levels are significantly lower. Treatment with Ginsenoside Rg1 in vivo inhibits IκBα phosphorylation, reduces NF-κB nuclear translocation and upregulates PPAR-γ expression. Ginsenoside Rg1 (G-Rg1) and Ginsenoside Rg2 (G-Rg2) reduce the escape latencies on the last two training days compared to the Alzheimer's disease (AD) model group (p<0.05). In the spatial exploration test, the total time spent in the target quadrant and the number of mice that exactly crossed the previous position of the platform are clearly shorter and lower, respectively, in the AD model group mice than in the normal control group mice (p<0.01), a trend that is reversed by treatment with Ginsenoside Rg1 and Ginsenoside Rg2 (Ginsenoside Rg1, p<0.01; Ginsenoside Rg2, p<0.05). Treatment with Ginsenoside Rg1 and Ginsenoside Rg2 effectively improve cognitive function of the mice that have declined due to AD. Ginsenoside Rg1 and Ginsenoside Rg2 reduce Aβ1-42 accumulation in APP/PS1 mice. In the Ginsenoside Rg1 and Ginsenoside Rg2 treated mice, the pathological abnormalities observed in the APP/PS1 mice are gradually ameliorated. Clear nucleoli and light brown, sparsely scattered Aβ deposits are visible. | ||||
| 临床实验 | N/A | ||||
1.Li N, et al. J Ginseng Res. 2016,40(1):9-17.
2.Wang P, et al. Aust Dent J. 2012,57(2):157-65.
3.Zhang L, et al. Oncotarget. 2017,8(33):55384-55393.
包装清单：| 产品编号 | 产品名称 | 包装 |
| SM6040-10mM | 人参皂苷Rg1 (98%, HPLC) | 10mM×0.2ml |
| SM6040-25mg | 人参皂苷Rg1 (98%, HPLC) | 25mg |
| SM6040-100mg | 人参皂苷Rg1 (98%, HPLC) | 100mg |
| － | 说明书 | 1份 |
-20℃保存，至少一年有效。固体粉末4℃保存，至少一个月有效。如果溶于非DMSO溶剂，建议分装后-80℃保存，预计6个月内有效。
注意事项：本产品可能对人体有一定的毒害作用，请注意适当防护，以避免直接接触人体或吸入体内。
本产品仅限于专业人员的科学研究用，不得用于临床诊断或治疗，不得用于食品或药品，不得存放于普通住宅内。
为了您的安全和健康，请穿实验服并戴一次性手套操作。
微信在线咨询
